BioSoteria Announces Call for Speaker Abstracts for the Sixth Annual Pacific Drug Safety Summit

Share Article

September Conference to Draw Global Biopharmaceutical Drug Safety Decision-Makers to San Francisco

News Image
PDSS has grown to become one of the most well attended drug safety conferences held in the US.

BioSoteria, Inc., Drug Safety and Risk Management Specialists, and organizers of the Annual Pacific Drug Safety Summit (PDSS), launched the PDSS website and has opened the invitation for abstract submission for an oral presentation during the main conference or corporate sponsor pre-conference tutorial at the 6th Annual PDSS. The conference will be held on September 20-21, 2012 at the Hilton San Francisco Airport Bayfront, Burlingame, CA. Sponsored pre-conference tutorials will be held on September 20, 2012 and oral presentations will take place during the main conference day on September 21, 2012. Speakers are encouraged to submit an abstract based on their work in the area of pharmacovigilance, risk management and/or pharmacoepidemiology

PDSS is one of the leading and fastest growing annual drug safety and pharmacovigilance conferences in the United States, drawing participants from US, Europe and Asia and annually held in San Francisco, home to a thriving pharmaceutical and biotechnology industry with the largest cluster of life sciences companies in the United States.

TOPICS PREVIOUSLY ADDRESSED AT PAST PDSS CONFERENCES INCLUDE:
RMP/REMS assessments and effective risk minimization tools
Solutions for streamlining Safety Operations
New or upcoming changes in US and EU regulations in pharmacovigilance compliance and inspections
Pharmacoepidemiology practice and applied study designs in pharmacovigilance
Safety signal detection methods and practical approaches
Other topics relevant to a pharmacovigilance and a drug safety industry practice audience

PAST SPEAKERS:
Hugh Tilson, MD, DrPH, Adjunct Professor of Public Health Leadership, Epidemiology, and Health Policy, UNC Gillings School of Global Public Health
Rebecca Wang, MD, Head of Drug Safety, Roche Global Pharma Development Center, China
Valerie Simmons, MD, BS, FFPM, Lilly QPPV Executive, Global Patient Safety, Eli Lilly & Co Ltd, UK
James Cross, PHD; Integrated Safety Risk Manager, Genentech
Judith Zander, MD; Executive Director, Patient Safety, AstraZeneca
Paul Coplan, Sc.D, MBA, Senior Director, Risk Management, Global Safety Surveillance and Epidemiology, Wyeth Pharmaceuticals
Robin Geller, PhD; Director of Risk Management, Global Pharmacovigilance, Baxter Healthcare Corporation
Catherine Hardalo, MD, VP, Clinical Development, Cadence Pharmaceuticals
Tobias Peschel, MD, PhD, MBA, VP, Drug Safety & Public Health, Gilead Sciences
Bethany Van Veen, Director, Safety Operations Drug Safety Risk Management, InterMune, Inc.
Eleanor Segal, MD, VP, Medical Safety Officer, Actelion Pharmaceuticals Ltd.
Gregory M. Bogdan, PhD, Research Director—RADARS®, Rocky Mountain Poison & Drug Center—Denver Health
Julie Acquafredda, MBA, Senior Project Manager PV, Takeda Global R&D
Cathy Sigler, DVM, PhD; Sr. Director, Safety, Epidemiology, Registries & Risk Management, United Biosource Corporation
Mary Mease, RPH, MPH, Senior Director Medical Affairs, Epidemiology & Outcomes Research, Quintiles
Brian Edwards, MD; Principal Consultant in Pharmacovigilance and Drug Safety, NDA Regulatory Science Ltd.

“PDSS has grown to become one of the most well attended drug safety conferences held in the US. Our speakers and attendees have represented over 50 pharmaceutical, biotechnology, medical device companies as well as vendors and service providers from around the globe, sharing diverse practices and challenges facing drug safety professionals in today’s dynamic regulatory environment. Our networking sessions and practical approach to our Program Committees’ selected topics and speakers have been winning elements in the success of PDSS. We invite you to participate by expressing your interest in an oral presentation by submitting an abstract to the PDSS website.” – Sally Van Doren, PharmD, President and Chief Executive Officer, BioSoteria, Inc.

Those interested in an oral presentation during the main conference day may submit an abstract for consideration by the PDSS Program Committee at http://www.PacificDrugSafetySummit.com

For those corporate sponsors who wish to host a pre-conference tutorial, please go to http://www.PacificDrugSafetySummit.com to register your sponsorship.

About BioSoteria
Founded in 2007 with a strong vision of a progressive drug safety and pharmacovigilance consulting services and education, BioSoteria serves the outsourcing needs of the pharmaceutical industry. From strategic risk management consulting services and full-service drug safety operational capabilities to world-class award winning pharmacovigilance training and education programs, BioSoteria provides unmatched experience, expertise, and leadership to support your company’s efforts to maximize your product’s benefit-risk profile. For more information and to learn more about BioSoteria’s drug safety services and training programs go to http://www.biosoteria.com.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Les Williams
BioSoteria, Inc.
(866) 660-5553 x 22
Email >
Visit website